Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma

Anticancer Res. 2013 Mar;33(3):755-62.

Abstract

Background/aim: To assess poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 together with radiation for the treatment of neuroblastoma.

Materials and methods: Clonogenic survival assays were used to assess MK-4827, radiation and combination thereof in four neuroblastoma cell lines. In vivo efficacy was tested in a murine xenograft model of metastatic neuroblastoma. In vivo targeted inhibition and biological effects included measurement of cleaved caspase-3, γ-H2AX, and Ki 67 by immunohistochemistry (IHC) and poly-ADP-ribose by Enzyme-Linked Immunosorbent Assay.

Results: Treatment of neuroblastoma cell lines reduced clonogenicity and resulted in additive effects with radiation. In vivo treatment with MK-4827 and radiation prolonged survival (p<0.01) compared to single modalities. In vivo superiority of MK-4827 plus radiation was further documented by significant elevations of cleaved caspase-3 and γ-H2AX in tumors from the combination group compared to single modality cohorts.

Conclusion: Combination of MK-4827 and radiation might provide effective therapy for children with high-risk neuroblastoma.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Caspase 3 / metabolism
  • Cell Line, Tumor
  • Chemoradiotherapy
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Histones / analysis
  • Humans
  • Indazoles / therapeutic use*
  • Mice
  • Neoplasm Metastasis
  • Neuroblastoma / enzymology
  • Neuroblastoma / pathology
  • Neuroblastoma / therapy*
  • Piperidines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Radiation-Sensitizing Agents / therapeutic use*

Substances

  • Enzyme Inhibitors
  • H2AX protein, human
  • Histones
  • Indazoles
  • Piperidines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Radiation-Sensitizing Agents
  • Caspase 3
  • niraparib